Correlogic, FDA To Discuss Status Of OvaCheck Ovarian Cancer Test
This article was originally published in The Gray Sheet
Executive Summary
FDA is requesting a meeting with Correlogic Systems to clarify the regulatory path to market for the OvaCheck early-stage ovarian cancer test
You may also be interested in...
Laboratory Stakeholders Urge FDA To Ditch IVDMIA Guidance, Pursue Rule
FDA should start over in its efforts to claim regulatory oversight of a new class of high-tech laboratory-developed tests through a guidance document and begin a formal rulemaking process, diagnostic industry stakeholders said at a Feb. 8 hearing
Laboratory Stakeholders Urge FDA To Ditch IVDMIA Guidance, Pursue Rule
FDA should start over in its efforts to claim regulatory oversight of a new class of high-tech laboratory-developed tests through a guidance document and begin a formal rulemaking process, diagnostic industry stakeholders said at a Feb. 8 hearing
PMA Required For OvaCheck Software, FDA Tells Correlogic
Correlogic plans to pull OvaCheck software from lab facilities and do the analysis in-house to avoid FDA regulation of the firm's ovarian cancer blood test